CDW8 Grantwriting and Specific Aim Critiques

Program: Career Development Workshops
Translational Session
Sunday, April 3, 2016: 7:00 PM-9:00 PM
Harbor BR2 (The Westin)

Registration is required for this session:
$30 (Food Provided)


Dolores M Shoback, University of California San Francisco, San Francisco, CA

Dolores Shoback trained in Internal Medicine at the Johns Hopkins University School of Medicine and performed a clinical and research fellowship in Endocrinology/Hypertension at Harvard Medical School before joining the faculty of the University of California, San Francisco. She is currently Professor of Medicine at the UCSF and Staff Endocrinologist at the San Francisco Veterans Affairs Medical Center. She is Associate Director of the Diabetes, Endocrinology and Metabolism Fellowship Training Program at UCSF. She is engaged in basic research on the mechanisms underlying the regulation of parathyroid hormone secretion with specific interest in the role of calcium-sensing receptors in parathyroid cells. She is also involved in cell-based studies and knockout mouse model systems studying the role of calcium-sensing receptors in the control of bone cell and chondrocyte differentiation. Her clinical activities and clinical research interest focus on metabolic bone diseases, parathyroid disorders, and osteoporosis. She has participated in investigations into the role of calcium receptor activation in the control of parathyroid hormone hypersecretion due to primary hyperparathyroidism and parathyroid carcinoma. She has served as Associate Editor of the Journal of Clinical Endocrinology and Metabolism (2004-2010) and as co-editor of the 8th (2007) and 9th editions (2011) of Greenspan’s Basic and Clinical Endocrinology by the Lange Publications. She has co-authored over 130 papers, reviews and editorials. She has served the Endocrine Society including as Clinical Chair (2008) and overall Chair (2009) Annual Meetings of the Endocrine Society. She has participated in the development of Guidelines for the management of primary hyperparathyroidism (2008, 2013), of postmenopausal osteoporosis (2013-15), and of hypoparathyroidism (2013-2015).

William T Schrader, Ph.D., NIEHS NIH, Research Triangle Pk, NC

Dr. William T. Schrader is a biochemist and molecular endocrinologist. His research interests have dealt with the structure, function and regulation of the steroid receptor superfamily. He received the Ph.D. in Biology from Johns Hopkins University in 1969, and then did post-doctoral research at Vanderbilt Medical School before joining the faculty at Baylor College of Medicine in 1972. He was appointed Professor of Cell Biology in 1985 and became Assistant Dean of the Graduate School in 1991. He joined Ligand Pharmaceuticals in 1995 as Vice President for Endocrine Research where he directed drug discovery in the areas of female and male sex hormone receptor modulators. Several of these drugs have advanced to market or into human clinical trials. In 2000 he co-founded XenoPharm, Inc. and served as the company’s Chief Scientific Officer and Vice President for Research. The company’s technical platform commercialized assays based upon proteins of the liver and intestine that sense the presence of foreign small molecules, including drugs and environmental substances. Dr. Schrader joined the National Institute of Environmental Health Sciences in 2003 as Deputy Scientific Director. In that role he deals extensively with postdoctoral training and career development. He is a member of the Laboratory of Reproductive and Developmental Toxicology of NIEHS. His past research interests center on the mechanism of action of tissue-selective nonsteroidal androgen receptor modulators and other substances that affect sex hormone developmental pathways. Prior to closing his own research lab in 2009, his studies had identified photoactivable ligands of the androgen receptor that can induce apoptosis only when the cells are irradiated with the appropriate light wavelengths, by triggering production of reactive oxygen species and DNA damage. An author of over 100 scientific papers, he has served on editorial boards, study sections and advisory panels for educational, governmental and for-profit organizations.

Ronald N Margolis, PhD, NIDDK and ADDS Office, Los Angeles, CA

Dr. Margolis recently retired from the Division of Diabetes, Endocrinology and Metabolic Diseases in the National Institute of Diabetes, Digestive, and Kidney Diseases at the NIH. He is now a consultant for NIDDK and for the Associate Director for Data Science, NIH working on the Data Discovery Index and BD2K. Dr. Margolis completed his doctoral training at the SUNY Health Sciences Center at Syracuse, and did post-doctoral training at the University of Virginia before joining the NIH.

Nothing to Disclose: DMS, RNM Disclosure Not Provided: WTS

After this session, attendees will be able to:

  • Understand the importance of each grant component, with special focus on the specific aims.
  • Prepare an application timeline to build resources and collect preliminary data to support their proposal.
  • Understand institutional commitment with the candidate in terms of facility use, faculty availability, and educational/training opportunities.
  • Understand the components of a strong specific aim section.
  • Discuss critiques of individually submitted specific aims